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Editorial
W
orld AIDS Day, the annual 
December 1 commemoration, 
ﬁrst took place in 1988 under 
the auspices of the Joint United Nations 
Programme on HIV/AIDS [1]. At that 
time few had recognized the epidemic’s 
impending global scope or envisaged 
how to provide AIDS treatment in 
developing countries. During the 
previous year, the United States Food 
and Drug Administration (FDA) had 
licensed zidovudine (AZT), the ﬁrst 
drug shown to be effective for treating 
HIV. AZT, which quickly became 
available in North America and Europe, 
provided modest hope for the ﬁrst 
time since the initial reports of AIDS in 
1981. Taken as a single drug every four 
hours round the clock, it could prolong 
life by half a year or more [2]. 
Twenty years later, HIV treatment 
has the potential to become one 
of medicine’s success stories. 
Combination anti-HIV therapies, 
referred to generically as highly active 
antiretroviral therapy (HAART), began 
to appear around 1996. Although costly 
and not without adverse effects, these 
“cocktails” have proved so effective 
that many who narrowly escaped death 
from AIDS in the mid-1990s are now 
facing the usual health concerns of 
advancing age. Although emergence 
of drug-resistant virus creates ongoing 
challenges, HIV treatment has 
continued to advance, as evidenced by 
the development of more convenient 
treatment regimens, and by FDA 
approval in 2007 of drugs from two new 
mechanistic classes: the ﬁrst integrase 
inhibitor and the ﬁrst chemokine 
receptor blocker. 
On the global scale, 2007 has seen 
further progress in the impressive 
effort to address ﬁnancial and logistical 
barriers to providing HIV treatment in 
low-resource settings. Although some 
5 million people remain in need of 
HAART, and a recent systematic review 
found that many who begin HAART in 
developing countries do not continue 
treatment [3], the fact that more than 
2 million people in low- and middle-
income countries are now receiving 
HAART marks signiﬁcant progress. 
In this context of global progress 
toward HIV treatment, the ofﬁcial 
theme of World AIDS Day 2007 
appropriately calls on “Leadership” to 
“Keep the Promise” of universal access 
to HIV care and services. 
Pounds of much-needed treatment, 
however, should not obscure the fact 
that precious ounces of prevention 
remain elusive: interrupting HIV 
transmission remains one of the world’s 
greatest scientiﬁc challenges. Indeed, 
in contrast to the progress made in 
treatment, World AIDS Day 2007 marks 
the end of a particularly sobering 
year in HIV prevention science, 
particularly in the area of female-
controlled methods, which have long 
been recognized as key to interrupting 
HIV transmission when social and 
economic disempowerment prevent 
women from insisting on condoms. 
January brought the announcement 
that two developing country trials 
of the vaginal microbicide cellulose 
sulfate had to be stopped because of 
an increased risk of HIV infection in 
women using the product [4,5]. The 
result was disappointingly reminiscent 
of the nonoxynol-9 vaginal microbicide 
trial that ended with a similar outcome 
in 2000 [6]. Another setback to female-
controlled prevention came in July 
with the report that providing latex 
diaphragms and gel together with 
male condoms to women in southern 
Africa gave no additional protection 
against HIV compared with condoms 
alone [7]. September brought more 
bad news: the early cessation of a major 
international HIV vaccine trial when 
interim analysis found that the vaccine, 
Merck’s trivalent adenovector product, 
appeared no better than placebo in 
preventing HIV infection [8]. Again 
the disappointment was familiar; in 
2003 the ﬁrst vaccine studies designed 
to assess protection against HIV in 
humans, using the VaxGen envelope 
products, were completed with no 
convincing evidence of efﬁcacy.
In the area of behavioral prevention, 
a 2007 systematic review of available 
reports [9] found that abstinence-
only programs, incorporated into 
many US and developing country 
HIV programs as a condition of US 
government funding, have been 
ineffective in reducing HIV risk in high-
income countries. However, a study 
of abstinence-plus programs (which 
promote condom use as an alternative 
when abstinence fails) found the latter 
programs to be more promising [10]. 
In 2007, US-supported treatment 
programs directly or indirectly provided 
HAART to more than a million people 
in developing countries, and provided 
more general HIV care and prevention 
services to millions more. To assure 
success in HIV prevention, it is time for 
leaders of the US effort to act on the 
scientiﬁc evidence and end political 
requirements for abstinence-only 
funding.
In perhaps the year’s most 
convincing results regarding HIV 
prevention, clinical trials in Uganda 
and Kenya, conﬁrming an earlier trial 
from South Africa [11], showed that 
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circumcision of adult men reduced 
their risk of acquiring HIV by about 
half over the subsequent two years 
[12,13]. However, even if this level 
of protection can be realized in the 
face of uncertain acceptance rates for 
circumcision and despite increased 
risk taking that may result from 
expectations of protection following 
circumcision, the risk reduction for a 
given male would still be no better than 
that of condom use for those who will 
use them. In turn, the effectiveness of 
circumcision—hardly a recent surgical 
technique—invites comparison to 
state-of-the-art research in immunology 
and virology, which have yet to deliver 
anything close to a reliable 50% 
reduction in risk of acquiring HIV 
through sexual exposure. Despite 
efforts of thousands of volunteers and 
expenditures of many tens of millions 
of dollars on clinical prevention trials 
ending in 2007, protection against 
sexual acquisition of HIV remains 
decidedly low-tech and frustratingly 
ﬁxated on the phallus.
In terms of short-term beneﬁt, then, 
it could be argued that basic research 
funding should instead be redirected 
toward condom education programs. In 
the long term, however, more deﬁnitive 
prevention methods are desperately 
needed to bring the AIDS crisis to an 
end, and we must not give up working 
toward a breakthrough in prevention 
comparable to the treatment advances 
of the past decade. New microbicides 
and vaccines are being developed 
and tested, trials of pre-exposure 
prophylaxis are under way, and more 
basic research in HIV epidemiology 
and pathogenesis continues to advance. 
The essential need for global 
dissemination and discussion of 
research reports is nowhere better 
illustrated than in the response to the 
vast complexity of the AIDS pandemic. 
PLoS Medicine has published many 
papers on HIV/AIDS, is featuring 
several new papers [14–20] in this 
World AIDS Day issue, and will publish 
several more over the coming weeks. 
For announcements and discussion 
of these upcoming articles in PLoS
Medicine as well as papers on HIV/AIDS 
in PLoS ONE, we invite our readers 
to check, and comment via, the PLoS
Medicine blog (http://www.plos.org/
cms/plosmedicine/).  
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